High plasma adiponectin is associated with increased pulmonary blood flow and reduced right ventricular function in patients with pulmonary hypertension

Dongling Luo¹†, Pengyuan Chen²†, Ziyang Yang¹†, Yongheng Fu³, Yigao Huang¹, Hezhi Li⁴, Jimei Chen⁵*, Jian Zhuang⁵* and Caojin Zhang¹*

Abstract

Background: Adiponectin is a biomarker closely related to heart failure. However, its role in pulmonary hypertension remains unclear. In this study, we investigated the association between adiponectin and hemodynamic abnormalities, right ventricular function in patients with congenital heart disease associated pulmonary hypertension (CHD-PH).

Methods: Patients with CHD-PH were enrolled in this cross-sectional study. Linear regression analysis was performed to assess the association between adiponectin, N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) and different clinical parameters. Results were depicted as beta-estimates(β) with 95%-confidence intervals (95% CI). In addition, mediation and receiver operating characteristic curve analyses were used to analyze the relationships among adiponectin, NT-proBNP and right ventricular function.

Results: A total of 86 CHD-PH patients were included. The overall mean adiponectin concentration was 7.9 ± 5.8 μg/ml. Log adiponectin was positively correlated with pulmonary circulation index (ß = 2.2, 95% CI 0.5, 4.0), log NT-proBNP (ß = 0.22, 95% CI 0.04, 0.41) and inversely with the tricuspid annular plane systolic excursion (TAPSE, ß = -4.7, 95% CI -8.6, -0.8). The mediation analysis revealed the association between NT-proBNP and TAPSE was fully mediated by adiponectin (total effect c = -5.4, 95% CI -9.4, -1.5, p = 0.013; direct effect c’ = -3.7, 95% CI -7.5, 0.1, p = 0.067). Additionally, the efficiency of adiponectin for detecting right ventricular dysfunction was not inferior to NT-proBNP (AUC = 0.84, 95% CI 0.67–1.00 vs AUC = 0.74, 95% CI 0.51–0.97, p = 0.23).

(Continued on next page)
Conclusions: Adiponectin is closely correlated with pulmonary blood flow and right ventricular function and may be a valuable biomarker for disease assessment in patients with pulmonary hypertension.

Keywords: Congenital heart disease, Pulmonary hypertension, N-terminal pro-brain natriuretic peptide, Adiponectin, Right ventricular function

Background
Pulmonary hypertension (PH) of variable degree is commonly accompanying with congenital heart disease (CHD) [1]. Closure on time can reverse, or even cure the disease. However, if not detected, the chronic exposure to high blood flow and pressure could trigger remodeling of the pulmonary vessels and finally leads to right heart failure [2]. Unfortunately, patients with PH are often asymptomatic until right ventricular dysfunction has developed, at which point irreversible remodeling may have occurred and the chance for shunt closure would have been lost [3].

Though plenty of biomarkers assessing the reversibility or disease severity have been reported in previous work, only N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) correlates well with hemodynamic parameters and survival in PH patients and thus has been incorporated in clinical PH guidelines [4]. Recent studies suggest a positive association between adiponectin (APN) and NT-proBNP in heart failure patients [5, 6]. Furthermore, adiponectin has been found to be elevated in patients with pulmonary hypertension [7, 8] and positively correlated with increased blood flow and vascular resistance [9].

However, whether plasma adiponectin correlates with hemodynamics in patients with congenital heart disease associated pulmonary hypertension (CHD-PH) or is just as a confounder accompanying with increased NT-proBNP, has not been examined. Thus, in the present study we investigated the correlation between plasma adiponectin and hemodynamic abnormalities, right ventricular function in patients with CHD-PH and analyzed the potential relationship between NT-proBNP and adiponectin.

Methods
Study population
Eligible CHD patients were included in this cross-sectional study, from June 1st, 2016 to January 1st, 2017 at Guangdong Cardiovascular Institute. Patients were included if systemic-pulmonary shunting cardiac defects were reported in their echocardiogram and required further assessment by the right heart catheterization (RHC) after evaluated by their physicians. Patents who refused to receive the RHC, younger than 18 years old or with a mean pulmonary arterial pressure (mPAP) less than 25 mmHg, as confirmed by the RHC, were excluded. Besides, patients with history of Down’s syndrome, severe valvular heart disease, connective tissue disease or chronic thromboembolism disease, were also excluded in this study. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approval by the Ethics Committee of Guangdong General Hospital. Written informed consent was obtained from each patient.

Data collection and adiponectin measurement
Demographic information, including age, gender, body mass index (BMI), systolic and diastolic blood pressure, were collected from the medical records. Blood samples were drawn from all participants at 6–8 am on the same day of the right heart catheterization (RHC) after an eight-hour overnight fasting. Biochemical measurements were performed in the laboratory of our institute. Biochemical parameters obtained for analysis included fasting blood glucose, serum creatinine, total cholesterol, triglyceride, high density lipoprotein (HDLC), low density lipoprotein cholesterol (LDLC) and NT-proBNP. NT-proBNP was quantitatively determined on the Roche Elecsys 2010 immunoassay analyzer, using electrochemiluminescence immunoassay technique in our laboratory.

For adiponectin measurement, 2 ml blood was drawn during the process of RHC and collected in plastic tubes to which disodium ethylenediamine tetraacetatic acid (EDTA) were added. The tubes were immediately taken to the laboratory, centrifuged at degree centigrade for separation of the plasma, and the plasma was then frozen and stored at −80 degree centigrade until analysis. Serum adiponectin levels were measured using a commercially available monoclonal and recombinant human adiponectin (R&D systems, Abingdon, UK). The intra-assay coefficient of variation (CV) was <5% and the inter-assay CV was <10%.

Echocardiograph
Echocardiograph was performed one day to one week before RHC using a commercially available probe and system (PHILIPS IE33). The echocardiographic indices, including left atrium dimension (LA), left ventricular end-diastolic dimension (LVEDD), left ventricular endsystolic dimension (LVESD), right atrium dimension (RA) and right ventricular end-diastolic diameter (RVEDD) at the midlevel, were measured according to the
guidelines of the American Society of Echocardiography [10]. The left ventricular ejection fraction (LVEF) was measured using Simpson’s biplane method. Tricuspid annular plane systolic excursion (TAPSE) and systolic velocity of lateral tricuspid annulus displacement (S’) were measured to represent for the right ventricular function. In the present study, either TAPSE < 16 mm or S’ < 10 cm/s was considered as reduced right ventricular function or right ventricular dysfunction [11]. Due to the large quantity of patients in China, indexes for right heart ventricular function, like TAPSE, S’, were not routinely assessed and only evaluated in patients with enlarged right heart or potential risk of right ventricular dysfunction. Therefore, missing data for right ventricular function was inevitable in this study and thus we could only perform subgroup analysis for this part.

Right heart catheterization
The right heart catheterization was performed by two experienced experts in our institute. The right atrium pressure (RAP), pulmonary artery pressure (PAP) and pulmonary artery wedge pressure (PAWP) were measured via the 6-French MP catheter. Blood samples were aspirated from superior vena cava, inferior vena cava, pulmonary artery and left heart system. Oxygen saturation of the blood sample was determined by using a standard blood gas analyzer (GEM Premier 3000). Subsequently, oxygen contents of the arterial and venous blood were calculated to determine the oxygen consumption (VO2). In the Fick method [12], the systemic (cardiac output, CO), pulmonary blood flow (pulmonary output, PO) and the corresponding cardiac index (CI), pulmonary index (PI) were estimated by the following equations:

a) Systemic blood flow (CO, L/min) = VO2 (ml/min) / (systemic arterial saturation- mixed venous oxygen saturation) *1.34 Hemoglobin(g/L) *10
b) Pulmonary blood flow (PO, L/min) = VO2 (ml/min) / (pulmonary venous oxygen saturation-mixed venous oxygen saturation) *1.34 Hemoglobin(g/L) *10
c) Cardiac index (CI, L/min/m²) = CO(L/min) / Body surface area (m²)
d) Pulmonary index (PI, L/min/m²) = PO(L/min) / Body surface area (m²)

Pulmonary vascular resistance (PVR) was calculated by mean pulmonary arterial pressure divided by the cardiac output.

Statistical methods
Results were expressed as mean ± standard deviation for continuous variables or as number of patients and percentages for categorical variables. Differences between continuous variables were assessed using student’s t-test. Categorical variables were compared among groups by the chi-square test or Fisher’s test, as appropriate. Because serum levels of adiponectin and NT-proBNP were not normally distributed, log 10 scale transformation of adiponectin and NT-proBNP were used in this study. Correlation between log adiponectin and log NT-proBNP was assessed by using the Pearson’s correlation analysis. Subsequently, linear regression models were used to estimate the non-adjusted or adjusted (age, gender, BMI, creatinine, TRIG/HDLC and glucose levels) association between adiponectin, NT-proBNP and echocardiographic, hemodynamic parameters.

Mediation analysis was performed to assess the potential mechanistic relationship between NT-proBNP and adiponectin on right ventricular function. In the mediation model, linear regression analysis was performed. a is the coefficient relating the independent variable to the mediator, b is the coefficient relating the mediator to the dependent variable adjusted for the independent variable, c’ is the coefficient relating the independent variable to the dependent variable adjusted for the mediator [13]. In order to eliminate the potential effects of confounders, this model was adjusted by age, gender, BMI, creatinine, TRIG/HDLC and glucose level.

Receiver operating characteristic (ROC) curve analyses were performed and the area under the curve (AUC) was calculated to evaluate the diagnostic efficiency of APN and NT-proBNP for right ventricular dysfunction. The Z-test was also performed to determine the statistical difference of the ROC curve. All p-values were 2-sided, and a value at p < 0.05 was considered statistically significant. All analyses were performed using Empower(R) (www.empowerstats.com, X&Y solutions, inc. Boston MA) and R (http://www.R-project.org).

Results
Of the 203 eligible patients, 117 had a mean pulmonary arterial pressure less than 25 mmHg and were excluded. The mean age of the study population was 35.8 ± 13.2 years old and 68% (59/86) were female. The overall mean plasma APN level was 7.9 ± 5.8 μg/ml and NT-proBNP was 468.6 ± 1011.5 pg/ml. Among the included 86 CHD-PH participants, 52 were caused by atrial septal defect (ASD), 21 by ventricular septal defect (VSD), 9 by patent ductus arteriosus (PDA) and 4 by coexisting of PDA and VSD or ASD. 58% (50/86) of them were in the class of NYHA I-II while the remaining 42% were in NYHA III-IV. Finally, for the included patients, 28 (32.5%) received shunt closure by percutaneous intervention, 25(29.0%) received open heart surgery and 30 (34.9%) started on targeted therapy (either monotherapy
or combined therapy of endothelin antagonist, prosta-

noids, phosphodiesterase 5 inhibitor). Three patients

refused to receive surgical managements and were closely

followed up after discharged. Other demographic and

clinical data are presented in Table 1.

Association between APN and different clinical

parameters

On the Pearson’s correlation analyses, the result revealed

that log adiponectin was positively correlated with log

NT-proBNP ($r = 0.41, p < 0.001$, Fig. 1). Table 2 presents

the linear regression analyses between log adiponectin

and different clinical parameters. There were no statisti-

cally significant correlations between log adiponectin

and pulmonary vascular resistance, cardiac index, mixed

venous oxygen saturation, mean right atrial pressure or

the cardiac structure of the left side. Interestingly, log

adiponectin levels were positively correlated with pul-

monary circulation index, even after adjustment for age,

gender, BMI, creatinine, TRIG/HDLC and glucose levels.

In addition, log adiponectin levels correlated positively

with RVEDD but negatively with TAPSE and $S'$. 

Association between NT-proBNP and different clinical

parameters

Also depicted in Table 2, log NT-proBNP was shown to

be positively correlated with mean right atrial pressure,

mean pulmonary artery pressure, dimension of the left

atrium and right atrium, right ventricle end-diastolic

dimension and negatively correlated with cardiac index,

left ventricular ejection fraction and TAPSE, either in

adjusted or non-adjusted models. Though the associ-

ation of log NT-proBNP and pulmonary vascular resist-

ance was not statistically significant in the non-adjusted

model, a positive correlation was observed after adjust-

ment for age, gender, BMI, creatinine, TRIG/HDLC and glucose level. Of note, no significant correlation was

observed between log NT-proBNP and pulmonary circu-

lation index.

Association between NT-proBNP, APN and right

ventricular function

As mentioned previously, log adiponectin was positively

correlated with log NT-proBNP. Since both log NT-

proBNP and log adiponectin were associated with TAPSE,
a mediation analysis was performed. As illustrated in Fig. 2, the regression coefficients between log NT-

proBNP and log adiponectin ($a = 0.22, 95\% CI 0.04$, 

0.41, $p = 0.023$), log adiponectin and TAPSE ($b = -6.2$, 

95\% CI -11.0, -1.4, $p = 0.02$) were both significant. The
total effect of log NT-proBNP on TAPSE became smaller when potential mediator log APN was included in
the model (total effect $c = -5.4$, 95\% CI -9.4, -1.5, $p = 0.013$; direct effect $c' = -3.7$, 95\% CI -7.5, 0.1, $p =$

| Table 1 Baseline characteristic of the included patients |
|---------------------------------|-----------|
| Clinical characteristics        | Valid cases, n(%) | Values |
| Age, years                      | 86 (100)   | 35.8 ± 13.2 |
| Gender, female                  | 86 (100)   | 59 (68%)  |
| BMI, kg/m2                      | 86 (100)   | 21.2 ± 4.0 |
| Laboratory measurements         |            |          |
| Hemoglobin, g/l                 | 86 (100)   | 1392 ± 22.9 |
| Adiponectin, ug/ml              | 86 (100)   | 7.9 ± 5.8 |
| NT-proBNP, pg/ml                | 72 (84)    | 468.6 ± 1011.5 |
| Glucose, mmol/l                 | 86 (100)   | 4.9 ± 1.4  |
| Creatinine, umol/l              | 86 (100)   | 64.2 ± 15.1 |
| CHOL, mmol/l                    | 81 (94)    | 4.4 ± 0.8  |
| TRIG, mmol/l                    | 81 (94)    | 1.2 ± 0.9  |
| HDLC, mmol/l                    | 81 (94)    | 1.2 ± 0.2  |
| LDLC, mmol/l                    | 81 (94)    | 2.8 ± 0.7  |
| TRIG/HDLC                       | 81 (94)    | 1.1 ± 1.2  |
| Echocardiography                |            |          |
| LVEF,%                          | 86 (100)   | 63.6 ± 9.9 |
| LA, mm                         | 86 (100)   | 35.9 ± 7.7 |
| LVEDD, mm                       | 86 (100)   | 44.3 ± 10.1 |
| LVESD, mm                       | 86 (100)   | 27.9 ± 8.3 |
| RA, mm                         | 86 (100)   | 56.8 ± 15.8 |
| RVEDD, mm                       | 86 (100)   | 60.4 ± 10.4 |
| TAPSE, mm                       | 41 (48)    | 21.0 ± 5.4 |
| $S'$, cm/s                      | 41 (48)    | 13.4 ± 3.9 |
| Right heart catheterization     |            |          |
| mRAP, mmHg                      | 86 (100)   | 5.8 ± 2.9 |
| mPAP, mmHg                      | 86 (100)   | 41.7 ± 23.7 |
| PAWP, mmHg                      | 86 (100)   | 9.7 ± 2.9 |
| MOS,%                           | 86 (100)   | 70.0 ± 10.5 |
| PVR, wood units                 | 86 (100)   | 5.7 ± 5.9 |
| PI, L/min/m2                    | 86 (100)   | 6.8 ± 3.3 |
| CI, L/min/m2                    | 86 (100)   | 3.7 ± 1.0 |
| QP/QS                           | 86 (100)   | 1.9 ± 0.9 |
| RP/RS                           | 86 (100)   | 0.3 ± 0.3 |

Abbreviation: BMI body mass index, CHOL cholesterol, TRIG triglyceride, HDLC high density lipoprotein cholesterol, LDLC high density lipoprotein cholesterol, TRIG/HDLC the ratio of TRIG and HDLC, LVEF left ventricular ejection fraction, LA left atrium, LVEDD left ventricular end-diastolic dimension, LVESD left ventricular end-systolic dimension, RA right atrium, RVEDD right ventricle end-diastolic dimension, TAPSE tricuspid annular plane systolic excursion, $S'$ systolic velocity of lateral tricuspid annulus displacement, RVFAC right ventricular functional area change, mRAP mean right atrial pressure, mPAP mean pulmonary arterial pressure, MOS mixed venous oxygen saturation, PVR pulmonary vascular resistance, PI pulmonary circulation index, CI cardiac index, QP/QS the ratio of pulmonary circulation and systemic circulation blood flow, RP/RS the ratio of pulmonary vascular resistance and systemic vascular resistance.
0.067). These results revealed that the association between NT-proBNP and right ventricular dysfunction, as assessed by TAPSE, was fully mediated by APN. In addition, as depicted in Fig. 3, the diagnostic efficiency of adiponectin for detecting right ventricular dysfunction was not inferior or even probably superior to NT-proBNP (AUC = 0.84, 95% CI 0.67–1.00; AUC = 0.74, 95% CI 0.51–0.97, respectively, \( p = 0.23 \)).

### Discussion

In the present study, adiponectin levels were found to be positively correlated with the pulmonary circulation

#### Table 2 Linear regression analysis of adiponectin, NT-proBNP and different clinical parameters

| Clinical Parameter | Log Adiponectin | Log NT-proBNP |
|--------------------|-----------------|---------------|
|                    | Non-adjusted    | Adjusted      | Non-adjusted    | Adjusted      |
| mRAP               | 1.2 (−0.4, 2.8) | 0.1 (−1.5, 1.7) | 0.903 (0.1, 1.7) | 0.3 (0.3, 0.8) |
| mPAP               | 7.7 (−5.2, 20.6) | 3.8 (−10.5, 18.1) | 0.601 (0.6, 1.2) | 0.3 (0.3, 0.6) |
| MOS                | 3.5 (−2.2, 9.2) | 5.5 (−0.9, 11.9) | 0.096 (−0.3, 1.6) | 0.03 (0.0, 0.6) |
| PVR                | 0.6 (−2.7, 3.8) | −1.1 (−4.0, 1.8) | 0.71 (0.4, 1.2) | 0.15 (−0.1, 0.5) |
| PI                 | 2.2 (0.5, 4.0) | 2.1 (0.2, 4.1) | 0.036 (0.0, 0.6) | 0.04 (−0.1, 0.2) |
| CI                 | 0.1 (−0.5, 0.6) | 0.2 (−0.4, 0.9) | 0.477 (−0.2, 1.0) | 0.06 (−0.2, 0.3) |
| LA                 | 4.3 (−0.0, 8.6) | 4.2 (−0.6, 9.0) | 0.089 (0.0, 0.7) | 0.2 (−0.2, 0.6) |
| LVEDD              | 2.4 (−3.3, 8.2) | 3.5 (−3.2, 10.2) | 0.311 (0.1, 0.6) | 0.62 (0.5, 0.7) |
| LVESD              | 3.6 (−1.1, 8.3) | 3.8 (−1.5, 9.0) | 0.164 (0.0, 0.3) | 0.17 (0.1, 0.3) |
| LVEF               | −8.5 (−13.9, −3.1) | −8.3 (−13.6, −2.9) | 0.004 (−0.2, 0.1) | 0.00 (−0.2, 0.2) |
| RA                 | 10.4 (16.2, 19.2) | 7.5 (−2.0, 16.9) | 0.126 (0.0, 0.2) | 0.00 (−0.1, 0.2) |
| RVEDD              | 9.5 (5.9, 15.0) | 7.2 (1.2, 13.2) | 0.022 (0.0, 0.1) | 0.00 (−0.1, 0.1) |
| TAPSE              | −4.7 (−8.6, −0.8) | −4.9 (−9.2, −0.5) | 0.036 (−0.2, 0.1) | 0.00 (−0.2, 0.1) |
| S′                 | −3.0 (−5.9, −0.2) | −3.7 (−6.7, −0.7) | 0.024 (−0.2, 0.1) | 0.00 (−0.2, 0.1) |

**Abbreviation:** mRAP mean right atrial pressure, mPAP mean pulmonary arterial pressure, MOS mixed venous oxygen saturation, PVR pulmonary vascular resistance, PI pulmonary circulation index, CI cardiac index, LVEF left ventricular ejection fraction, LA left atrium, LVEDD left ventricular end-diastolic dimension, LEVSD left ventricular end-systolic dimension, RA right atrium, RVEDD right ventricle end-diastolic dimension, TAPSE tricuspid annular plane systolic excursion, S′ systolic velocity of lateral tricuspid annulus displacement

Adjusted, adjusted by age, gender, BMI, creatinine, TRIG/HDL-C and glucose levels

Depicted are beta-estimates with 95%-confidence intervals and \( p \)-value from linear regression analysis
blood flow and negatively with the right ventricular function in patients with CHD-PH. In addition, when compared with NT-proBNP, an at least non-inferior diagnostic efficiency for right ventricular dysfunction was observed for adiponectin and further, the association of NT-proBNP and right ventricular dysfunction was probably mediated by the effect of adiponectin.

**Adiponectin and CHD-PH**

Patients with CHD-PH had significantly higher serum adiponectin (7.9 ± 5.8 μg/ml) as compared to a group of healthy adults from our hospital (3.61 ± 2.87 μg/ml) and a healthy control group of a Korean study (5.99 ± 2.75 μg/ml), with similar age, BMI and sex distribution [14]. This suggests a role of adiponectin in patients with CHD-PH. Adiponectin is an adipokine, which was known to be almost exclusively produced and secreted by adipocytes. However, in addition to adipocytes, various other cell types secrete adiponectin [15]. Recent studies have reported adiponectin expression in cardiomyocytes and endothelial cells [16–18]. It’s been reported that adiponectin could reduce accumulation of inflammatory cells, inhibit proliferation of vascular smooth muscle cells and thus exerts a cardio-protective effect in pulmonary hypertension [19, 20]. However, emerging clinical observations demonstrate that plasma APN levels are elevated in patients with PH and positive correlated with pulmonary vascular resistance (PVR) and

---

**Fig. 2** The mediation effect of adiponectin (APN) on the association between NT-proBNP and right ventricular dysfunction. a is the coefficient between log NT-ProBNP and log adiponectin (a = 0.22, 95%CI 0.04, 0.41, p = 0.023). b is the coefficient between log adiponectin and TAPSE (b = -6.2, 95%CI -11.0, - 1.4, p = 0.02). c is the coefficient between log NT-proBNP and TAPSE (c = - 5.4, 95%CI -9.4, - 1.5, p = 0.013). The coefficient c’ between log NT-proBNP and TAPSE becomes insignificant when log adiponectin is included in the model (c’ = - 3.7, 95%CI -7.5, 0.1, p = 0.067). These results reveal that the association between NT-proBNP and right ventricular dysfunction, as assessed by TAPSE, is fully mediated by APN. TAPSE, tricuspid annular plane systolic excursion.

**Fig. 3** Receiver operating characteristic curve of adiponectin and NT-proBNP. There’s a trend that adiponectin exhibited a better diagnostic efficiency as compared to NT-proBNP in patients with right ventricular dysfunction (AUC = 0.84, 95%CI 0.67–1.00; AUC = 0.74, 95%CI 0.51–0.97, respectively, p = 0.23). AUC, area under the curve.
pulmonary arterial systolic pressure (PASP) [8]. Furthermore, the elevated adiponectin is associated with poorer cardiac function and higher mortality in heart failure patients [21, 22]. Though we did not find significant correlation between adiponectin and PVR as well as the pulmonary arterial pressure, we first demonstrated that adiponectin was closely related to pulmonary circulation blood flow. As suggested in previous studies, increased pulmonary blood flow is regarded the essential trigger for PH development and should closely be monitored [23, 24]. Additionally, adiponectin was positively associated with right ventricular dimension and negatively with right ventricular function, which suggested APN might be an important indicator for the pulmonary-right ventricular system.

These findings were in line with the previous studies [11, 25, 26]. The level of adiponectin was higher in patients with right ventricular dysfunction and inversely correlated with TAPSE [8] or even an early RV dysfunction indicator, the right ventricular free wall global strain [27]. Furthermore, the concentration of APN correlated well with the change of RV function. Also, in the studies conducted by Serrano-Ferrer. et al. and Isobe S. et al., adiponectin levels reduced after improvement of right heart overload and restoration of the RV function [8, 27]. Besides, high plasma adiponectin was associated with a lower peak VO₂ and higher VE/ VCO₂-slope, parameters closely related to PH mortality [3, 26]. All these results underlined the importance of plasma adiponectin in assessing the right ventricular function in patients with CHD-PH.

However, the reasons for these observations remain to be unraveled. Some authors suggest that adiponectin plays a permissive role in the structural and metabolic cardiac remodeling and thus accelerates the transition to heart failure [28]. While others state that the association of hyperadiponectinemia and increased mortality in heart failure was a phenomenon of ‘adiponectin resistance’, characterized by downregulation of AdipoR1 and phosphorylation of the downstream proteins like AMPK and P38MAPK [29]. However, it is unclear why this occurs and needs further elucidation.

**Adiponectin and NT-proBNP**

NT-proBNP is a well-recognized biomarker that has been recommended in the existing PH guidelines [4]. Consistent with previous studies, our study also demonstrated a positive correlation between NT-proBNP and PVR as well as mPAP. In addition, NT-proBNP positively correlated with adiponectin and negatively with the left and right ventricular function, as assessed by LVEF and TAPSE. However, unlike adiponectin, no significant relation of NT-proBNP to pulmonary blood flow was observed in the current study.

Recently, the association between NT-proBNP and adiponectin has been examined in adults with heart failure [5, 30, 31]. Some studies stated that the association of APN and heart failure vanished after adjusting for NT-proBNP [31], some revealed that high APN level was associated with increased risk of mortality, independent of plasma NT-proBNP [22], while Dai Z et al. found an improved diagnostic value of conjunction of NT-proBNP and APN for heart failure [30]. While in our study, the diagnostic efficiency of adiponectin for detecting right ventricular dysfunction was not inferior or even probably better than NT-proBNP. With respect to a possible mechanism accounting for these observations, studies are going on. As reported by Tsukamoto et al., increased adiponectin gene expression and adiponectin secretion were observed in cultured human adipocytes in response to natriuretic peptide treatment [32]. However, some other studies revealed that adiponectin was present in damaged cardiomyocytes and might be directly synthesized by and released from the failing heart [16, 17, 25].

Although whether the elevation of adiponectin is the result of increased NT-proBNP or as an active contributor to worsening heart failure progression remains unclear, some findings suggested that the effects of NT-proBNP might relate to adiponectin signaling [33]. As demonstrated by Masuch A et al., the effect of NT-proBNP on lipid profile was partially mediated by adiponectin [33]. By using the mediation effect model, we also found a mediation effect of adiponectin on the association of NT-proBNP and right ventricular function. From this perspective of view, it is important to more fully investigate the effects of adiponectin and NT-proBNP on cardiac dysfunction based on basic experiments.

**Limitation**

Due to the retrospective nature of this study, no causality of the interrelations between these parameters can be determined. In addition, limited by the small sample size in a single-center study, generalization of these findings to other types of PH necessitates further validation. Although TAPSE is a widely used index for right ventricular systolic performance, it’s only partially representative of global RV function and not as accurate and precise as that assessed by cardiac magnetic resonance [11]. What’s more, half of our patients had missing data for the echocardiographic assessment of the right ventricular function. However, patients with missing data had similar hemodynamic information, lower adiponectin level and less severe change of the right side of the heart (data depicted in Additional file 1), which indicated less right ventricular dysfunction and a higher specificity would be observed if all of them were included in the ROC analysis. Lastly, adiponectin has multiple isoforms (low,
medium and high molecular weight (HMW)), with the HMW isof orm being the most abundant and presenting the greatest biological properties [6, 34–36]. However, we did not evaluate the oligomeric state of the adiponecin. Although in a report of adiponectin and left ventricular function, total circulating adiponectin reflects well with the HMW adiponectin on the heart [37], we could not confirm this result in the present study owing to insufficient data. Therefore, further studies must be performed to better understand the role of different oligomeric state in patients with pulmonary hypertension and to clarify whether pulmonary hypertension causes alterations in expression or profile of adiponectin.

Conclusion
Unlike other types of PH, earlier detection of pulmonary arteriopathy or right ventricular dysfunction could provide timely shunt closure and thus largely improve the survival of patients with CHD-PH. From the current findings of this study, adiponectin was closely correlated with pulmonary blood flow and right ventricular function, which might be a valuable biomarker for assessing the hemodynamics and prognosis in CHD patients with PH. However, knowledge gaps remain and further investigation is warranted.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12890-020-01233-4.

Additional file 1: Table S1. Baseline characteristics in patients with (RVF group) or without (missing group) data of right ventricular function (RVF).

Abbreviations
CHD-PH: congenital heart disease associated pulmonary hypertension; NT-proBNP: N-terminal pro-Brain Natriuretic Peptide; TAPSE: Tricuspid annular plane systolic excursion; PH: Pulmonary hypertension; CHD: Congenital heart disease; APN: Adiponectin; RHC: Right heart catheterization; mPAP: Mean pulmonary arterial pressure; BMI: Body mass index; HDLC: High-density lipoprotein; LDL/C: Low-density lipoprotein cholesterol; TRIG/HDL/C: the ratio of triglyceride and high density lipoprotein; LA: Left atrium dimension; LVEDD: Left ventricular end-diastolic dimension; LVEF: Left ventricular ejection fraction; S': Systolic velocity of later tricuspid annulus displacement; RAP: Right atrium pressure; PAWP: Pulmonary arterial wedge pressure; VO2: Oxygen consumption; CO: Cardiac output; PO: Pulmonary output; CI: Cardiac index; PI: Pulmonary index; PVR: Pulmonary vascular resistance; ROC: Receiver operating characteristic; AUC: Area under the curve; ASD: Atrial septal defect; VSD: Ventricular septal defect; PDA: Patent ductus arteriosus; RV: Right ventricle; NYHA: New York Heart Association; PASP: Pulmonary arterial systolic pressure; AMPK: Adenosine S'-monophosphate-activated protein kinase; P38MAPK: P38 mitogen-activated protein kinase; HMW: High molecular weight

Acknowledgements
Not applicable

Authors’ contributions
LDL, CPV and YYZ contributed to the study design, patient enrollment, data collection, data analyses and manuscript drafting. FYH contributed to data collection, data analyses and adiponectin measurements. HYG and LHZ contributed to patient enrollment and data interpretation. ZCJ, CJM and ZJ contributed to study design, data interpretation and final approval of the manuscript. All authors have read and approved the manuscript.

Funding
This study was conducted with financial support from the National Nature Science Foundation of China (No. U1401255), the Science and Technology Department of Guangdong Province (No. 2014A0505030048, 2017A07010113 and 2017B0909004034, 2017B03014109), Guangdong Natural Science Foundation (2018A030313764) and the National Key Research and Development Program (No.2018YFC0102600). The funders had no role in the design of the study, the collection, analysis and interpretation of the data, or the preparation of the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approval by the Ethics Committee of Guangdong General Hospital. Written informed consent was obtained from each patient.

Consent for publication
Not applicable.

Competing interests
All authors declared no conflicts of interest (including financial, personal, religious, ideological, academic, intellectual, commercial or any other) in relation to this manuscript.

Author details
1. Department of Cardiology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangdong Cardiovascular Institute, Guangzhou, China. 2. Department of Cardiology, Guangdong General Hospital’s Nanhai Hospital, the Second Hospital of Nanhai District Foshan City, Foshan, China. 3. Department of Laboratory, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangdong Provincial People’s Hospital, Guangdong Academic of Medical Sciences, Guangzhou, China. 4. Department of Echocardiography, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangdong Cardiovascular Institute, Guangzhou, China. 5. Department of Cardiac Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangdong Cardiovascular Institute, Guangzhou, China.

Received: 16 January 2020 Accepted: 13 July 2020
Published online: 30 July 2020

References
1. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007;115(8):1039–50.
2. van der Feen DE, Bartelds B, de Boer RA, Berger RMF. Assessment of reversibility in pulmonary arterial hypertension and congenital heart disease. Heart. 2019;105(4):276–82.
3. DeFaria YD, Stefanescu Schmidt AC, Eisman AS, Serafs JD, Naqvi M, Youniss MA, et al. Impaired right ventricular reserve predicts adverse cardiac outcomes in adults with congenital right heart heart disease. 2018;104(24):2044–50.
4. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67–119.
5. Pervanidou P, Margeli A, Akalestos A, Sakka S, Kanaka-Gantenbein C, Papassotiriou I, et al. Associations between circulating N-terminal pro-brain-natriuretic peptide and survival in adults with congenital heart disease and right ventricular dysfunction. Circulation. 2007;115(15):1878–84.
6. Papassotiriou I, et al. Associations between circulating N-terminal pro-brain-natriuretic peptide and survival in adults with congenital heart disease and right ventricular dysfunction. Circulation. 2007;115(15):1878–84.
natriuretic peptide (NT-proBNP) and adiponectin concentrations depend on obesity level in female adolescents: gender dimorphic findings. Horm Metab Res. 2009;41(11):829–33.

6. Tsutamoto T, Tanaka T, Sakai H, Ishikawa C, Fujii M, Yamamoto T, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J. 2007;28(14):1723–30.

7. Santos M, Reis A, Goncalves F, Ferreira-Pinto MJ, Cabral S, Torres S, et al. Adiponectin levels are elevated in patients with pulmonary arterial hypertension. Clin Cardiol. 2014;37(1):21–5.

8. Isobe S, Kataoka M, Kawakami T, Fukuda K. Adiponectin in chronic thromboembolic pulmonary hypertension. Circ J. 2018;82(3):1466–8.

9. Omar T, Nagaoka T, Yoshida A. Relationship between retinal blood flow and serum Adiponectin concentrations in patients with type 2 diabetes mellitus. Invest Ophthalmol Vis Sci. 2015;56(6):4143–9.

10. Rudski LG, Lai WW, Afifalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report of the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685–713 quiz 86–9.

11. Zhou X, Ferraro F, Contaldi C, Bosone E. Right ventricular size and function in chronic heart failure: not to be forgotten. Heart Fail Clin. 2019;15(2):205–17.

12. Davies NJ, Shinebourne EA, Scallan MJ, Sopwith TA, Denison DM. Pulmonary vascular resistance in children with congenital heart disease. Thorax. 1984;39(12):896–900.

13. MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annu Rev Psychol. 2010;61:587–614.

14. Kim K, Jang EH, Kim AY, Fava M, Mischolou D, Papakostas GI, et al. Pretreatment peripheral biomarkers associated with treatment response in panic symptoms in patients with major depressive disorder and panic disorder: a 12-week follow-up study. Compr Psychiatry. 2019;95:152140.

15. Pierrotta F, Nigro E, Meliga M, Costigliola A, D’Agnano V, Daniele A, et al. Pulmonary Hypertension and Obesity: Focus on Adiponectin. Int J Mol Sci. 2019;20(4):912.

16. Takano H, Ohtani J, Koda Y, Kita Y, Nakamura T, Mende A, et al. Adiponectin is released from the heart in patients with heart failure. Int J Cardiol. 2009;132(2):221–6.

17. Pincero R, Iglesias MJ, Galleiro R, Raghay K, Eiras S, Rubio J, et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett. 2005;579(23):5163–9.

18. Yoo JK, Hwang MH, Luttrell MJ, Kim HK, Meade TH, English M, et al. Higher levels of adiponectin in vascular endothelial cells are associated with greater brachial artery flow-mediated dilation in older adults. Exp Gerontol. 2015;63:1–7.

19. Medoff BD. Fat, fire and muscle–the role of adiponectin in pulmonary hypertension. Pulm Pharmacol Ther. 2013;26(4):420–6.

20. Weng M, Raher MJ, Leyton P, Combs TP, Scherer PE, Bloch KD, et al. Adiponectin decreases pulmonary arterial remodeling in murine models of vascular inflammation and remodeling. Pulm Pharmacol Ther. 2013;26(4):420–6.

21. Loukari ID, Vassilakos IK, Dintzas A, Mavrogenis A, Kalistratos MS, Manginas A, et al. High plasma adiponectin is related to low functional capacity in patients with chronic heart failure. Int J Cardiol. 2010;144(2):230–1.

22. Kistop C, Faber J, Galatas S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112(2):1756–62.

23. Dickinson MG, Bartelds B, Borgdoff MA, BM B. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol. 2013;305(1):L1–L14.

24. van der Feen DE, Bartelds B, de Boer RA, RWM B. Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. Eur Heart J. 2017;38(26):2034–41.

25. Tanger WH, Sheehan TA, Tong W, Wang Z, Troughton RW, Borowski AG, et al. Nitric oxide bioavailability and adiponectin production in chronic systolic heart failure: relation to severity of cardiac dysfunction. Transl Res. 2013;162(1):26–33.

26. Szabo T, Scherbakov N, Sandek A, Kung T, von Haehling S, Lainscak M, et al. Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis. Nutr Metab Cardiov Dis. 2014;24(1):50–6.